Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by RelevantStockon Aug 09, 2020 6:12pm
131 Views
Post# 31385102

RE:RE:RE:RE:RE:RE:RE:RE:RE:The next week will be monumental.

RE:RE:RE:RE:RE:RE:RE:RE:RE:The next week will be monumental.
SAGDollar wrote: I think Mercer will be a teriffic partner to market Aristotle


Ah yeah definitely the best. Aristotle will benefit the most to the employers that offer insurance plans to a large pool of workers, allowig them to save huge costs on cancer treatments (in USA). I am here mostly for covid revenue for the moment though, as much as I like Aristotle and believe in its future. Glad they are working on following the prospectus plan, I have them in high respect for helping fight the pandemic, but I'll need to better see a big lighthouse to stay onboard after the Q3 hype. I was 100% believer but would have liked a follow up PR or two, after a (first) very abrupt ER for q4 q1.
Bullboard Posts